IMPACT OF COMORBIDITY BURDEN ON LONG-TERM QUALITY OF LIFE FOLLOWING SEVERE VIRAL LOWER RESPIRATORY TRACT DISEASE HOSPITALIZATION
Author(s)
Tom Wilkinson, PhD1, Josefine Persson, PhD2, Mia Harvey, BSc3, Liane Gillespie-Akar, MSc3, Rebecca Hardy-Woods, BSc3, Yao Qiao, PhD4, Klas Bergenheim, PhD2.
1University of Southampton, Southampton, United Kingdom, 2AstraZeneca, Gothenburg, Sweden, 3Adelphi Real World, Bollington, United Kingdom, 4AstraZeneca, Gaithersburg, MD, USA.
1University of Southampton, Southampton, United Kingdom, 2AstraZeneca, Gothenburg, Sweden, 3Adelphi Real World, Bollington, United Kingdom, 4AstraZeneca, Gaithersburg, MD, USA.
OBJECTIVES: Evaluate the impact of comorbidity burden on long-term quality of life (QoL) in patients hospitalised for severe viral lower respiratory tract disease (LRTD) requiring ICU-level care and oxygen supplementation.
METHODS: Data were drawn from the Adelphi Real World Disease Specific Programme™, a cross-sectional survey of physicians and their patients discharged 6-24 months prior to the survey following severe viral LRTD requiring ICU-level care and oxygen supplementation. Data were collected across France, Germany, Italy, Spain, UK, US and Japan between February and July 2024. Descriptive analyses summarised patient demographics and clinical characteristics, and patient-reported QoL outcomes using EQ-5D-5L utility score (range -1 to 1). Linear regression analyses assessed associations between comorbidity burden (comorbidity count and Charlson Comorbidity Index [CCI]) and QoL.
RESULTS: Ninety-three physicians reported data for 193 patients. Mean (standard deviation; SD) age was 67.1 (11.49) years; 59.1% were female and 93.5% were White. Mean (SD) time since hospital admission was 11.9 (4.2) months, and 40.7% received invasive mechanical ventilation during hospitalisation.
At admission, mean (SD) CCI score was 0.8 (1.5) (60.1% score 0, 21.1% 1, 18.7% ≥2) and mean (SD) comorbidity count of 2.5 (2.0) (10.4% none, 26.4% 1, 23.3% 2. 39.9% ≥3). Cardiovascular (61.1%) and respiratory (46.1%) conditions were most common. Mean (SD) EQ-5D-5L was 0.72 (0.24).
Increasing comorbidity burden was significantly associated with lower EQ-5D-5L utility scores (comorbidity count: β = -0.04, p=0.001; CCI: β = -0.27, p<0.05). Significant interaction terms were observed between cardiovascular and neurological (β = -0.27, p<0.001), and respiratory and neurological conditions (β = -0.31, p=0.007) in linear regression analysis of EQ-5D.
CONCLUSIONS: Long-term QoL impairment following severe LRTD is driven by comorbidity burden, with a compounding negative effect when conditions co-occur. This highlights multimorbidity as a key outcome determinant and the need for improved post-LRTD care management strategies.
METHODS: Data were drawn from the Adelphi Real World Disease Specific Programme™, a cross-sectional survey of physicians and their patients discharged 6-24 months prior to the survey following severe viral LRTD requiring ICU-level care and oxygen supplementation. Data were collected across France, Germany, Italy, Spain, UK, US and Japan between February and July 2024. Descriptive analyses summarised patient demographics and clinical characteristics, and patient-reported QoL outcomes using EQ-5D-5L utility score (range -1 to 1). Linear regression analyses assessed associations between comorbidity burden (comorbidity count and Charlson Comorbidity Index [CCI]) and QoL.
RESULTS: Ninety-three physicians reported data for 193 patients. Mean (standard deviation; SD) age was 67.1 (11.49) years; 59.1% were female and 93.5% were White. Mean (SD) time since hospital admission was 11.9 (4.2) months, and 40.7% received invasive mechanical ventilation during hospitalisation.
At admission, mean (SD) CCI score was 0.8 (1.5) (60.1% score 0, 21.1% 1, 18.7% ≥2) and mean (SD) comorbidity count of 2.5 (2.0) (10.4% none, 26.4% 1, 23.3% 2. 39.9% ≥3). Cardiovascular (61.1%) and respiratory (46.1%) conditions were most common. Mean (SD) EQ-5D-5L was 0.72 (0.24).
Increasing comorbidity burden was significantly associated with lower EQ-5D-5L utility scores (comorbidity count: β = -0.04, p=0.001; CCI: β = -0.27, p<0.05). Significant interaction terms were observed between cardiovascular and neurological (β = -0.27, p<0.001), and respiratory and neurological conditions (β = -0.31, p=0.007) in linear regression analysis of EQ-5D.
CONCLUSIONS: Long-term QoL impairment following severe LRTD is driven by comorbidity burden, with a compounding negative effect when conditions co-occur. This highlights multimorbidity as a key outcome determinant and the need for improved post-LRTD care management strategies.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR140
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Infectious Disease (non-vaccine), No Additional Disease & Conditions/Specialized Treatment Areas, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)